BioNexus Gene Lab Corp gross margin has been in long-term decline. The average rate of decline per year is -10.7%.
The historical rank and industry rank for BioNexus Gene Lab's Gross Margin % or its related term are showing as below:
BGLC'
s Gross Margin % Range Over the Past 10 Years
Min: 11.52 Med: 14.39 Max: 44.09
Current: 13.61
During the past 6 years, the highestGross Margin % of BioNexus Gene Lab was 44.09%. The lowest was 11.52%. And the median was 14.39%.
BGLC's Gross Margin % is ranked worse than 74.45% of 1507
companies
in the Chemicals industry
Industry Median: 22.25
vs BGLC: 13.61
BioNexus Gene Lab had a gross margin of 11.75% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BioNexus Gene Lab was -10.70% per year.
BioNexus Gene Lab Gross Margin % Historical Data
The historical data trend for BioNexus Gene Lab's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Gross Margin %
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Gross Margin % Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioNexus Gene Lab had a gross margin of 11.75% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BioNexus Gene Lab Gross Margin % Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 